Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.

Wicker, L S; Boltz, R C; Matt, V; Nichols, E A; Peterson, L B; Sigal, N H

Wicker, L S; Boltz, R C; Matt, V; Nichols, E A; Peterson, L B; Sigal, N H.

Affiliation

Wicker LS; Department of Immunology Research, Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.

Eur J Immunol ; 20(10): 2277-83, 1990 Oct.

Article in En | MEDLINE | ID: mdl-1700753

Subject(s)

Anti-Bacterial Agents/pharmacology; B-Lymphocytes/drug effects; Cyclosporins/pharmacology; Immunosuppressive Agents/pharmacology; Lymphocyte Activation/drug effects; Animals; Antibodies, Monoclonal; B-Lymphocytes/immunology; Cell Cycle/drug effects; Cell Survival/drug effects; Female; Histocompatibility Antigens Class II/immunology; Kinetics; Mice; Mice, Inbred C57BL; Polyenes/pharmacology; Sirolimus; Tacrolimus

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: B-Lymphocytes / Lymphocyte Activation / Cyclosporins / Immunosuppressive Agents / Anti-Bacterial Agents Limits: Animals Language: En Journal: Eur J Immunol Year: 1990 Document type: Article Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links